These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 22898678

  • 1. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.
    Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
    [Abstract] [Full Text] [Related]

  • 2. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
    Brose MS, Capdevila J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, Sugitani I, Taylor MH, Wang Z, Wirth LJ, Worden FP, Bernard J, Caferra P, Colzani RM, Liu S, Schlumberger M.
    Endocr Relat Cancer; 2024 Aug 01; 31(8):. PubMed ID: 38828895
    [Abstract] [Full Text] [Related]

  • 3. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
    Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.
    J Clin Oncol; 2012 Jan 10; 30(2):134-41. PubMed ID: 22025146
    [Abstract] [Full Text] [Related]

  • 4. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE.
    Lancet Oncol; 2010 Jul 10; 11(7):619-26. PubMed ID: 20570559
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.
    J Clin Oncol; 2012 Apr 01; 30(10):1114-21. PubMed ID: 22370318
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN, Banaszynski ME, Kolesar JM.
    Am J Health Syst Pharm; 2013 May 15; 70(10):849-55. PubMed ID: 23640345
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C.
    Thyroid; 2021 Mar 15; 31(3):459-469. PubMed ID: 32781914
    [Abstract] [Full Text] [Related]

  • 13. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
    Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL.
    J Hepatol; 2012 May 15; 56(5):1097-1103. PubMed ID: 22245891
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vandetanib: in medullary thyroid cancer.
    Frampton JE.
    Drugs; 2012 Jul 09; 72(10):1423-36. PubMed ID: 22715896
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.
    Thyroid; 2015 Apr 09; 25(4):386-91. PubMed ID: 25627619
    [Abstract] [Full Text] [Related]

  • 18. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J.
    Lancet Oncol; 2021 Aug 09; 22(8):1126-1138. PubMed ID: 34237250
    [Abstract] [Full Text] [Related]

  • 19. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.
    J Clin Oncol; 2009 May 20; 27(15):2523-9. PubMed ID: 19332730
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.